{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T02:54:00Z","timestamp":1722308040117},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T00:00:00Z","timestamp":1408924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T00:00:00Z","timestamp":1408924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1038\/leu.2014.249","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T06:38:07Z","timestamp":1408948687000},"page":"2416-2418","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells"],"prefix":"10.1038","volume":"28","author":[{"given":"M","family":"Nieborowska-Skorska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Flis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Skorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,25]]},"reference":[{"key":"BFleu2014249_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1042\/CS20040336","volume":"109","author":"SB Marley","year":"2005","unstructured":"Marley SB, Gordon MY . Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci (Lond) 2005; 109: 13\u201325.","journal-title":"Clin Sci (Lond)"},{"key":"BFleu2014249_CR2","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1172\/JCI41246","volume":"120","author":"D Perrotti","year":"2010","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254\u20132264.","journal-title":"J Clin Invest"},{"key":"BFleu2014249_CR3","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2004.08.169","volume":"323","author":"N Sorel","year":"2004","unstructured":"Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG . Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004; 323: 728\u2013730.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu2014249_CR4","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1073\/pnas.1321173111","volume":"111","author":"DL Gibbons","year":"2014","unstructured":"Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci USA 2014; 111: 3550\u20133555.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2014249_CR5","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","volume":"121","author":"E Bolton-Gillespie","year":"2013","unstructured":"Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 2013; 121: 4175\u20134183.","journal-title":"Blood"},{"key":"BFleu2014249_CR6","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1038\/leu.2013.123","volume":"27","author":"M Nieborowska-Skorska","year":"2013","unstructured":"Nieborowska-Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T . Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia 2013; 27: 2253\u20132254.","journal-title":"Leukemia"},{"key":"BFleu2014249_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.leu.2405086","volume":"22","author":"H Konig","year":"2008","unstructured":"Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008; 22: 748\u2013755.","journal-title":"Leukemia"},{"key":"BFleu2014249_CR8","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1182\/blood-2011-10-385658","volume":"119","author":"M Nieborowska-Skorska","year":"2012","unstructured":"Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119: 4253\u20134263.","journal-title":"Blood"},{"key":"BFleu2014249_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","volume":"105","author":"JH Kim","year":"2005","unstructured":"Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D et al. Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717\u20131723.","journal-title":"Blood"},{"key":"BFleu2014249_CR10","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J 1997; 16: 6151\u20136161.","journal-title":"EMBO J"},{"key":"BFleu2014249_CR11","first-page":"1093","volume":"2","author":"SB Kondapaka","year":"2003","unstructured":"Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK . Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093\u20131103.","journal-title":"Mol Cancer Ther"},{"key":"BFleu2014249_CR12","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1128\/MCB.25.18.8001-8008.2005","volume":"25","author":"SY Ren","year":"2005","unstructured":"Ren SY, Bolton E, Mohi MG, Morrione A, Neel BG, Skorski T . Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR\/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 2005; 25: 8001\u20138008.","journal-title":"Mol Cell Biol"},{"key":"BFleu2014249_CR13","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T . Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868\u20135876.","journal-title":"Oncogene"},{"key":"BFleu2014249_CR14","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-04-2440","volume":"65","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1\/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65: 2422\u20132432.","journal-title":"Cancer Res"},{"key":"BFleu2014249_CR15","doi-asserted-by":"publisher","first-page":"e78453","DOI":"10.1371\/journal.pone.0078453","volume":"8","author":"SM Kornblau","year":"2013","unstructured":"Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D et al. Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One 2013; 8: e78453.","journal-title":"PLoS One"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014249","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:09:13Z","timestamp":1648742953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,25]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["BFleu2014249"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.249","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,25]]},"assertion":[{"value":"25 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}